OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TVRD
Tvardi Therapeutics, Inc.
There isn't enough reported data to score TVRD yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TVRD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Strong |
TVRD's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TVRD PE Valuation
TVRD has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TVRD Forward outlook
There aren't enough analyst estimates for TVRD to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TVRD on earnings quality, reporting a profit while its opponent remains loss making.
TVRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.79 | +$14.54 |
| Q1 2026 | -$3.10 | +$26.55 |
| Q4 2025 | -$5.59 | +$41.00 |
| Q3 2025 | -$9.64 | +$53.72 |
| Q2 2025 | -$17.33 | +$56.47 |
| Q1 2025 | -$29.65 | +$51.71 |
| Q4 2024 | -$46.59 | +$32.25 |
| Q3 2024 | -$63.36 | +$14.04 |
TVRD is still losing money, but far less than before: $2.79 per share over the past year, against $91.80 at its worst in early 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus up 20% for TVRD.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TVRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $2.6M | +20% |
| Q4 2024 | $1.5M | -52% |
| Q3 2024 | $2.6M | -47% |
| Q2 2024 | $991K | -86% |
| Q1 2024 | $2.1M | -65% |
| Q4 2023 | $3M | -7.9% |
| Q3 2023 | $4.9M | -55% |
| Q2 2023 | $6.9M | -70% |
TVRD's revenue is recovering but still below its 2020 peak: $3M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -93% | +1297 points |
| Q4 2024 | -373% | +713 points |
| Q3 2024 | -234% | +360 points |
| Q2 2024 | -1746% | -1280 points |
| Q1 2024 | -1390% | -941 points |
| Q4 2023 | -1085% | -125 points |
| Q3 2023 | -594% | -373 points |
| Q2 2023 | -466% | -447 points |
TVRD's operating margin was −93% last quarter, up 1297 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
TVRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | -$363K |
| Q4 2025 | -$5.7M | -$1.6M |
| Q3 2025 | -$4.3M | +$9.7M |
| Q2 2025 | -$8.9M | +$3.8M |
| Q4 2024 | -$4M | +$15.4M |
| Q4 2023 | -$19.4M | +$4.1M |
| Q2 2022 | -$4.5M | +$16.5M |
| Q1 2022 | -$25.6M | -$1.8M |
TVRD has burned cash in almost every quarter: −$25M over the past year, against −$40M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TVRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +11% | +926K shares |
| 3 years | +525% | +7.9M shares |
| 5 years | +575% | +8M shares |
| Available history | +659% | +8.1M shares |
TVRD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TVRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -1.0x | Net Cash |
| Q2 2021 | -3.2x | Net Cash |
| Q1 2021 | -1.9x | Net Cash |
| Q4 2020 | -5.7x | Net Cash |
TVRD has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TVRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 15.1 | Oversold |
TVRD's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TVRD PE vs Healthcare Sector
TVRD has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has stronger trend alignment. OSCR is above 5 of 5 weekly averages versus TVRD above 1 of 3.
TVRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.04 | 12% above |
| 20 week MA | $1.71 | 32% below |
| 50 week MA | $2.86 | 59% below |
TVRD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 50-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TVRD on returns for 2026, with the stronger performance.
TVRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $14.7 | $4.14 | -72% |
| 2026 YTD | $4.14 | $1.16 | -72% |
TVRD has finished every year since 2025 lower, and it's down 72% so far in 2026.